OSUR ORASURE TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1116463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.5%
TTM net income YoY19.5%
TTM EPS YoY14.8%
Revenue 3-yr CAGR-36.4%
Net income 3-yr CAGR—
Margins
Gross margin43.1%
Operating margin-43.8%
Net margin-41.7%
FCF margin-42.7%
EBITDA margin-35.8%
Returns
ROE-14.5%
ROA-12.6%
ROIC (approx.)-26.4%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio8.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $30.91M | $30.64M | $27.93M | $26.76M | $27.09M | $31.24M | $29.93M | $37.45M |
| Cost of revenue | $16.94M | $17.32M | $16.12M | $15.79M | $15.31M | $18.08M | $17.63M | $23.88M |
| Gross profit | $13.97M | $13.32M | $11.80M | $10.97M | $11.77M | $13.16M | $12.30M | $13.57M |
| R&D expense | $7.63M | $9.44M | $13.65M | $11.42M | $10.11M | $11.40M | $9.60M | $6.09M |
| SG&A expense | $11.99M | $14.43M | $14.56M | $9.82M | $11.08M | $12.68M | $14.10M | $12.90M |
| Operating income | -$12.96M | $5.44M | -$23.27M | -$20.10M | -$16.09M | -$18.03M | -$17.75M | -$12.42M |
| Pretax income | -$11.79M | $6.82M | -$21.72M | -$18.43M | -$13.29M | -$16.89M | -$15.97M | -$9.51M |
| Income tax | $708,000 | $55,000 | -$432,000 | $210,000 | $47,000 | $2.00M | -$456,000 | $758,000 |
| Net income | -$13.09M | $6.25M | -$22.38M | -$19.29M | -$13.71M | -$19.69M | -$16.04M | -$10.79M |
| EBITDA | -$10.76M | $7.81M | -$20.93M | -$17.70M | -$13.64M | -$15.50M | -$14.94M | -$9.93M |
| EPS (basic) | -0.19 | 0.09 | -0.32 | — | -0.19 | -0.26 | -0.21 | — |
| EPS (diluted) | -0.19 | 0.09 | -0.32 | — | -0.19 | -0.26 | -0.21 | — |
| Weighted avg. shares (diluted) | 69.00M | 70.16M | 69.67M | — | 73.00M | 74.54M | 74.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $148.24M | $160.58M | $176.96M | $199.28M | $216.48M | $234.58M | $247.57M | $267.76M |
| Receivables | $30.42M | $25.60M | $24.81M | $22.20M | $24.30M | $25.90M | $21.52M | $23.82M |
| Inventory | $30.42M | $30.07M | $30.31M | $31.06M | $33.40M | $33.38M | $35.68M | $34.20M |
| Current assets | $215.29M | $222.94M | $240.78M | $261.91M | $283.01M | $301.44M | $313.78M | $333.22M |
| PP&E, net | $36.51M | $38.58M | $37.86M | $39.18M | $40.80M | $42.16M | $43.16M | $45.10M |
| Goodwill | $42.74M | $42.72M | $43.05M | $43.36M | $41.31M | $41.74M | $40.45M | $40.33M |
| Intangibles | $18.76M | $18.84M | $18.94M | $19.05M | $17.20M | $17.27M | $17.31M | $17.43M |
| Total assets | $349.47M | $360.55M | $379.17M | $403.17M | $423.10M | $445.04M | $457.61M | $479.66M |
| Current liabilities | $25.10M | $25.12M | $44.08M | $39.80M | $40.25M | $42.35M | $25.42M | $33.48M |
| Total liabilities | $42.33M | $42.77M | $65.84M | $62.34M | $61.12M | $64.31M | $61.33M | $69.32M |
| Shareholders' equity | $307.13M | $317.78M | $313.32M | $340.83M | $361.98M | $380.72M | $396.28M | $410.34M |
| Shares outstanding | 69.04M | 68.97M | 69.40M | 70.39M | 72.27M | 73.73M | 75.11M | 74.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.87M | -$9.92M | -$13.89M | -$9.00M | -$10.07M | -$10.22M | -$19.73M | $109,000 |
| Capital expenditure | $1.67M | $2.43M | $913,000 | $922,000 | $919,000 | $1.94M | $420,000 | $456,000 |
| Free cash flow | -$12.55M | -$12.35M | -$14.81M | -$9.92M | -$10.99M | -$12.16M | -$20.15M | -$347,000 |
| Investing cash flow | -$1.67M | -$2.41M | -$913,000 | -$4.42M | -$821,000 | -$1.94M | $370,000 | -$5.49M |
| Financing cash flow | -$35,000 | -$2.25M | -$6.28M | -$5.11M | -$5.08M | -$5.80M | -$953,000 | -$111,000 |
| Depreciation & amortization | $2.20M | $2.37M | $2.34M | $2.40M | $2.45M | $2.53M | $2.81M | $2.49M |
| Stock-based compensation | $2.28M | $2.29M | $2.77M | $1.46M | $2.83M | $3.17M | $2.69M | $2.74M |
| Share buybacks | $0 | $2.00M | $5.00M | $5.04M | $5.00M | $4.06M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.